Copper-Related Disorders

Diagnostic Considerations

• The American Association for the Study of Liver Diseases recommends that Wilson's disease must be ruled out first in any patient under 40 years presenting with neurological symptoms and should be considered even in older patients with atypical presentations 1
• Serum ceruloplasmin <50 mg/L provides strong evidence for Wilson's disease, though 5-10% of patients may have normal levels, according to the American Association for the Study of Liver Diseases 3
• 24-hour urinary copper excretion typically >100 μg/day is a key diagnostic feature of Wilson's disease, as stated by the American Association for the Study of Liver Diseases 3
• The presence of Kayser-Fleischer rings is a pathognomonic sign when present with neurological symptoms, as noted by the American Association for the Study of Liver Diseases 1
• Acute or chronic copper poisoning presents with the same symptom triad and can occur from contaminated water, dietary supplements, or occupational exposure, according to the Academy of Nutrition and Dietetics 2
• Elevated serum copper levels are a distinguishing feature of acquired copper toxicity, as stated by the Academy of Nutrition and Dietetics 2
• Plasma copper <8 μmol/L indicates deficiency requiring repletion, according to the Academy of Nutrition and Dietetics 4
• The American Heart Association notes that true vertigo differs from light-headedness and suggests peripheral or central vestibular pathology 5
• The American Academy of Neurology recommends performing HINTS examination if stroke is suspected 6

Management Points

• The American Association for the Study of Liver Diseases recommends initiating chelation therapy with D-penicillamine 250-500 mg/day for Wilson's disease 2
• The Academy of Nutrition and Dietetics suggests oral copper supplementation 4-8 mg/day for repletion in cases of copper deficiency 4
• The American Association for the Study of Liver Diseases warns that neurological symptoms may initially worsen with penicillamine—do not discontinue therapy 7